NVS - Novartis AG ADR (NYSE Stock)
The multinational pharmaceutical company Novartis returns to biotech Zeltia attack and this time it's going more seriously than we might think, and in a few days we will see.
Novartis would have on the table a firm offer of 2,450 million euros, and this time saw the picture of going public, members of the board of Zeltia, it will be very difficult to reject this proposal as it makes some months this council is divided and some would sell their units very well to higher prices of EUR 4 that moves the action.
Its shareholders, large and small and tired of seeing that the action which should not rise, although they know the value of the company not represented in these 4 euros and that its value can only rise with the progress of their drugs and Yondelis sales partners like the Kutxa but I go into the 12 euros with nearly 7 million shares, Rosalia Mera about 10 euros to 10 million shares and certain funds about 6-8 euros with more than 20 million shares, and would welcome collect much of their investments, after so many years.
For two months all been good news in Zeltia, with the approval of its drug Yondelis for treatment of ovarian cancer in the European Union, with quarterly results that vanish every time and expect more losses into profits in 2010, and also with confirmation by the company that there will be no capital increase in Zeltia because they have enough funds on hand. But after all the good news, Zeltia moves in a range of 4 euros and little else.
Novartis, like some big drug companies know this very well, not only Zeltia cancer drugs also has its subsidiary Noscira Nypta phase II for treatment of Alzheimers and highly promising results, and if left to market sales of drug, turnover would have nothing to do with sales Yondelis would be very high, especially given that currently there is no treatment whatsoever to treat Alzheimers.
Over 10 major pharmaceutical drug Nypta are above, and are assessing their future effectiveness, and have signed private contracts with Zeltia to see the test data.
Although from Novartis Zeltia know that this shielded against any hostile bid for the block of voting rights that give them no more than 10%, but if they get 60-70% of the shares and that it could easily get there would be a war within the company and have the enemy inside, providing data on its drugs and progress, having access to all research data.
Zeltia hours are numbered, and any day we will raise with a hostile bid or agreed, because the board can no longer withstand the pressure above it, by large shareholders, small shareholders, and its President Mr. José Maria Fernandez Sousa give budge in no time.
|
Linear Mode
